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Randomized controlled trials involving natriuretic peptide administration in solid organ transplantation setting have shown
inconsistent effects for renal endpoints. We conducted a systematic review and meta-analysis of these trials to ascertain the role of
natriuretic peptides in the management of solid organ transplantation associated acute kidney injury (AKI). MEDLINE, EMBASE,
andGoogle scholarwere searched independently by two authors for randomized trials evaluating renal effects of natriuretic peptides
in solid organ transplantation settings. Two reviewers independently assessed the studies for eligibility and extracted the relevant
data. The pooled estimate showed that natriuretic peptide administration is associated with a reduction in AKI requiring dialysis
(odds ratio = 0.50 [0.26–0.97]), a statistically nonsignificant trend toward improvement in posttransplant creatinine clearance
(weighted mean difference = 5.5mL/min, [−1.3 to 12.2mL/min]), and reduction in renal replacement requirement duration
(weighted mean difference −44.0 hours, [−60.5 to −27.5 hours]). There were no mortality events and no adverse events related
to natriuretic peptides. In conclusion, administration of natriuretic peptides in solid organ transplantation may be associated
with significant improvements in renal outcomes. These observations need to be confirmed in an adequately powered, prospective
multicenter study.
1. Introduction
Acute kidney injury (AKI) is common in hospitalized
patients and is associated with significant morbidity and
mortality [1, 2]. Despite recent advances, outcomes from
AKI have not substantially changed in the last four decades
and the incidence of AKI is on the rise [3]. Solid organ
transplantation procedures (e.g., liver transplantation, heart
transplantation, lung transplantation, and combined solid
organ transplantations such as heart-lung transplant) are a
recognized cause of AKI and renal transplantation is also
frequently associated with AKI [4–10]. The incidence of AKI
after liver transplantation reportedly ranges from 12% to
67% depending upon the definition used [4, 11]. Dialysis
is required in up to 21% of the cases [4], and AKI in this
setting is associated with higher mortality [4, 11]. Similarly,
the incidence of AKI remains high in immediate postcardiac
transplantation setting as up to 1/3rd of patients develop AKI
[7]. Postischemic acute tubular necrosis is the most common
cause of persistent renal failure (also known as delayed
graft function) in the immediate postrenal transplant period
and remains a major obstacle for renal graft survival [12].
There remains an unmet need to explore novel therapeutic
agents and revisit some older agents to explore their role in
management of AKI in solid organ transplantation setting.
Natriuretic peptides are a family of peptides predom-
inantly synthesized in the atrial myocyte and then stored
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as three different prohormones: 126-amino acid atrial natri-
uretic peptide prohormone, 108-amino acid brain natriuretic
peptide prohormone, and 126-amino acid C-natriuretic pep-
tide prohormone [13–17]. Posttranslational modification of
atrial natriuretic peptide prohormone in the heart produces
atrial natriuretic peptide, which is a 28-amino acid peptide
with direct diuretic andnatriuretic effects in both animals and
humans [13–16]. Atrial natriuretic peptide has been shown
to block tubular reabsorption of sodium promoting natriure-
sis, reverse endothelin-induced vasoconstriction leading to
dilation of afferent arterioles, and inhibit renin-angiotensin
system [14–16, 18–20]. Post-translational modification of
atrial natriuretic peptide prohormone in the kidney produces
urodilatin with additional four amino acids at the N-terminal
[13–16]. Brain natriuretic peptide, a 32-amino acid peptide,
derived from brain natriuretic peptide prohormone, has
remarkable sequence homology to atrial natriuretic peptide
with only four amino acids being different in the amino acid
ring structure common to both peptides [13–16]. Brain natri-
uretic peptide also has diuretic, natriuretic, vasodilatory, and
aldosterone inhibiting properties [21]. C-natriuretic peptide,
derived fromC-natriuretic peptide prohormone, despite hav-
ing similar amino acid sequence as atrial natriuretic peptide
lacks any physiological effects on intrarenal sodiumhandling,
sodium excretion, aldosterone pathway, and hemodynamics
[13–16].
Despite the above described physiologic actions and
potential to reverse multiple factors involved in the patho-
genesis of solid organ transplantation associatedAKI (includ-
ing renal ischemia and hyperactivated renin-angiotensin-
aldosterone system), randomized controlled trials (RCTs)
evaluating the role of natriuretic peptides in this setting have
been largely underpowered and have produced conflicting
results [4, 6, 22–26]. In addition, natriuretic peptides, espe-
cially at high doses, are known to cause hypotension and
arrhythmias, complications that can potentially negate the
possible benefits [14–17, 27]. The purpose of this review was
to undertake a systematic analysis of randomized controlled
studies to ascertain the therapeutic potential of natriuretic
peptides in the management of AKI that occurs after solid
organ transplantation procedures.
2. Methods
2.1. Data Sources, Search Strategy, and Study Selection. We
performed this review as per the QUOROM statement
[28]. Two reviewers searched MEDLINE (1966 to August
2012), EMBASE (1980 to August 2012), and Google scholar
(in August 2012) for randomized controlled studies that
compared any form or dose of natriuretic peptide to placebo
or standard treatment (such as hydration and diuretics)
in adult (age >18 years) patients undergoing solid organ
transplantation surgery. To be included the studies had to
report at least one of the prespecified renal outcomes—
AKI requiring dialysis, postsurgery serum creatinine, or
creatinine clearance levels. To retrieve the eligible studies, we
employed the following search terms: natriuretic peptides,
atrial natriuretic peptide, ANP, urodilatin, anaritide, uralir-
itide, atriopeptin, brain natriuretic peptide, BNP, C-type
natriuretic peptide, surgery, operation, transplantation, organ
transplantation, acute renal failure, acute kidney failure, ARF,
acute renal insufficiency, acute kidney insufficiency, acute
kidney injury, AKI, acute tubular necrosis, ATN, and delayed
graft function.In addition, we studied reference lists and
bibliographical data from all retrieved articles and reviews
for any additional relevant material. There was no language
restriction.
Following studies were excluded: (1) nonrandomized
trials, (2) those evaluating the role of natriuretic peptides in
nontransplant surgical setting (e.g., cardiovascular surgeries
and radiocontrast nephropathy prevention), (4) experimental
animal studies, and (5) those that did not report the pre-
specified renal outcomes.
2.2. Data Extraction and Quality Assessment. Two review-
ers independently assessed the studies for eligibility and
extracted relevant data regarding study design and setting,
participant characteristics, and outcome measures using a
standardized data extraction form (SN and HK). There were
no disagreements between the 2 independent reviewers for
the extracted data. Only explicit descriptions of outcome
events were tabulated. If the required data could not be
obtained from the journal publication, then 2 separate attem-
pts at contacting original authors were made.
The results of the individual studies were reported in
many different ways, including mean and standard deviation
(SD), standard error of the mean (SEM), or interquartile
range (IQR). We converted standard error of the means and
interquartile ranges to standard deviation, using appropriate
formulae. We considered interquartile range to be 1.35 times
the standard deviation. Standard deviation was calculated as
square root of sample size multiplied by the standard error of
the mean. All data was converted to uniform measurements;
thus serum creatinine is presented as mg/dL and creatinine
clearance or glomerular filtration rate as mL/min.
The method of all included studies was rated by means of
the validated scale by Jadad et al. [29]. This scale considers
randomization, blinding, and withdrawal/dropouts. Studies
were considered to be of low quality if the Jadad score was
from 0 to 2, of moderate quality if the score was from 3 to
4, and of high quality if the score was 5. Study quality was
appraised by two reviewers independently and divergences
resolved by consensus.
3. Outcome Measures
The primary outcomes of interest for the current review
were posttransplantation AKI requiring dialysis and short
term mortality (30 day or in hospital). Secondary outcomes
analyzed included duration of dialysis requirement (hours),
incidence of AKI, and posttransplantation creatinine clear-
ance. AKI was defined as per the Acute Kidney Injury
Network criteria [30]. We also abstracted data regarding
adverse effects of natriuretic peptides such as hypotension
and arrhythmias.
3.1. Data Analysis and Quantitative Data Synthesis. We ana-
lyzed data as per guidelines in the Cochrane Reviewers’
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Handbook [31]. All the analyses were performed using Rev-
Man 4.2.10 (Cochrane Collaboration, Oxford, UK). Dichoto-
mous data outcomes from individual studies were ana-
lyzed according to the Mantel-Haenszel model to compute
individual odds ratio (OR) with 95% confidence intervals
(CI). Where continuous scales of measurement were used
to assess the effects of treatment, the weighted mean dif-
ference (WMD) was used. Treatment effects were pooled
with the fixed-effects model. Statistical significance was set
at the 2-tailed 0.05 level for hypothesis testing. Statistical
heterogeneity was analyzed using 𝐼2 test [32]. 𝐼2 values of
25%, 50%, and 75% correspond to low, medium and high
levels of statistical heterogeneity.We constructed funnel plots
to explore publication bias.
3.2. Sensitivity Analyses. Sensitivity analyses were conducted
by switching from fixed-effect to random-effect models and
by computing relative risks. We also planned to repeat the
analyses (if adequate number of studies were to be avail-
able) by restricting it to patients undergoing nonrenal solid
organ transplantation, restricting to high quality studies,
and restricting to studies that included participants with
preexisting renal impairment.
4. Results
Database searches and snowballing yielded a total of 123
citations. Excluding 98 nonrelevant titles and abstracts, we
retrieved 25 studies in complete form and assessed them
according to the selection criteria. A total of 18 studies
were further excluded, since they involved evaluation in
nonsolid organ transplant setting. Our analysis finally iden-
tified 7 eligible studies comprising total 238 participants (118
natriuretic peptide group; 120 control group) [4, 6, 22–26].
Characteristics of the included studies are summarized in
Table 1. Mean age of the participants was 44 years and 40%
participants were females. Four studies (135 participants)
evaluated the role of human atrial natriuretic peptide [4, 6,
23, 26]. Three studies (103 participants) evaluated the role of
urodilatin [22, 24, 25]. No eligible studies were identified that
involved administration of brain natriuretic peptide or C-
type natriuretic peptide. Natriuretic peptides were generally
given via intravenous infusion route, and one study included
administration in renal allograft renal artery followed by
intravenous infusion [23].The dosages of natriuretic peptides
varied widely amongst the studies; human natriuretic peptide
was typically administered at dosages from 0.0125𝜇g/kg/min
to 0.05 𝜇g/kg/min, and urodilatin was administered at dose
of 20 ng/kg/min or 40 ng/kg/min. The durations of natri-
uretic peptide administration also varied widely amongst the
studies from anywhere between 4 hours to 7 days. Control
intervention was placebo in all studies except in one where it
was furosemide infusion with potassium canrenoate [4].
Solid organ transplantation surgeries included liver trans-
plantation [4, 24, 25], renal transplantation [6, 23, 26], and
heart transplantation [22]. None of the studies were con-
ducted in the setting of combined solid organ transplantation
or in lung transplantation. Four studies were designed to
assess the effects of natriuretic peptides in patients with
preexisting impaired renal function [6, 23, 24, 26]. Natriuretic
peptide administration was started either at or immediately
after the surgery in all studies. None of the studies except one
[4] had no standardized criteria for initiation of dialysis, and
this decision was largely left to the treating clinicians in the
remaining studies.
Jadad scores for the included studies are outlined in
Table 1. The overall quality of the included studies was
suboptimal with only 2 studies being of high quality [22, 26].
In studies with moderate and low quality, descriptions of
randomization and blinding methods were poorly reported
[4, 6, 23–25]. All the included studies had single center
enrollment of patients, and none acknowledged support from
the pharmaceutical industry.
4.1. Primary Outcomes. Data on AKI requiring dialysis were
reported in all 7 studies. Pooled estimate showed that the use
of natriuretic peptide was associated with reduction in AKI
requiring dialysis (OR 0.50 [0.26–0.97], 𝐼2 = 0%) (Figure 1).
None of the studies reported any 30-day or in-hospital mor-
tality events; hence,meta-analyses could not be conducted for
this outcome.
4.2. Secondary Outcomes and Adverse Effects. Only one study
reported duration of dialysis requirement and in this study
use of natriuretic peptide was associated with a significant
reduction in the duration of dialysis requirement (WMD
−44.0 hours, [−60.5 to −27.5 hours]) [22]. Sufficient data were
not available from the individual RCTs to compute the AKI
incidence as defined by the Acute Kidney Injury Network
criteria; hence this outcome could not be analyzed. Two
studies reported data on postsurgery creatinine clearance
[6, 26]. Pooled analyses for this outcome showed a nonstatis-
tically significant trend towards improvement in creatinine
clearance in participants that received natriuretic peptides
(WMD 5.5mL/min, [−1.3 to 12.2mL/min]).
We analyzed adverse effect profile of natriuretic peptide as
reported in individual studies. None of the studies reported
any adverse events such as hypotension or arrhythmias in
either arm of the RCTs.
4.3. Sensitivity Analyses. Sensitivity analyses were performed
by switching from random-effect to fixed-effect models, and
by computing relative risks.These analyses did not change the
overall results for all the outcomes.
Further sensitivity analyses as originally proposed by rest-
ricting to nonrenal solid organ transplant settings, restricting
to studies with participants that have preexisting renal imp-
airment prior to the initiation of intervention, and restricting
to high quality studies were not conducted due to highly
limited number of small studies thatwere available to conduct
meta-analyses.
Assessment of validity and robustness of these findings
by means of a funnel plot suggested possibility of small study
publication bias (Figure 2).
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5. Discussion
AKI following a solid organ transplantation is a major cause
of morbidity and mortality [10]. Unfortunately, no effective
interventions are available to prevent or treat this condi-
tion, and thus there is an urgent need for development of
new agents. Multiple factors, including renal hypoperfusion,
hypovolemia, ischemia-reperfusion, neurohumoral includ-
ing renin-angiotensin system activation, and nephrotoxin
exposure especially anti-rejection medications, are known to
contribute to this renal dysfunction in organ transplantation
setting [4, 10]. The use of natriuretic peptides with their
properties noted in animal models such as vasorelaxation,
natriuresis, diuresis, and aldosterone inhibition appears to
be a potentially effective option to manage cardiovascular
surgery associated renal dysfunction [4, 13–17].
Our meta-analysis assessed the efficacy for renal out-
comes and safety of natriuretic peptides in patients undergo-
ing solid organ transplantation.Our comprehensive literature
review found that most studies addressing this topic are small
and lack the power to reach statistical significance on their
own for clinically meaningful outcomes (such as dialysis and
mortality). However, pooled analysis of the current available
evidence shows that the administration of natriuretic pep-
tides is associated with reduction in the postsurgery dialysis
requirement along with a possible reduction in postsurgery
dialysis duration and a nonstatistically significant trend
towards improvement in creatinine clearance in participants
that received natriuretic peptides. In this review, natriuretic
peptides were well tolerated with no reports of hypotension
and arrhythmias.
Larger and adequately powered studies designed to eval-
uate atrial natriuretic peptide in other settings, such as
acute tubular necrosis from conditions such as sepsis, have
been negative [33, 34]. Dose of atrial natriuretic peptide
preparations administered in these studies was much larger
(up to 0.20𝜇g/kg/minute) and was associated with signifi-
cantly higher incidence of hypotension [14–17]. When renal
perfusion pressure falls below 100mmHg, the renal blood
flow in the cortex and medulla decreases in response, and
that in the medulla is poorly autoregulated [35]. Under this
condition, atrial natriuretic peptide induced hypotension
could potentially negate the beneficial effects [14–17]. By
contrast, studies performed in solid organ transplantation
setting in our review administered lower doses of atrial
natriuretic peptide preparations and were not associated with
significant increase in adverse events. This differential risk
benefit ratio associated with dosing of natriuretic peptides
should be taken into consideration while planning further
RCTs. Future studies should also systematically collect data
on urine output and serum creatinine to compute incidence
of AKI as defined by the Acute Kidney Injury Network
criteria [30].
Our systematic review has limitations, similar to our
prior work that analyzed effects of natriuretic peptides in
other settings such as cardiovascular surgery [14–17, 31].
The outcomes considered in our review were not necessarily
the primary outcomes of interest to the study authors, and
hence the included studies were underpowered to detect any
significant difference for outcomes such as AKI requiring
dialysis. There were no uniform indications for dialysis in
most of the included trials and the decision to initiate
dialysis was left to the participating physicians. This may
have introduced potential confounding for AKI requiring
dialysis outcome analysis. Additionally,most included studies
were conducted prior to the year 2000, and considerable
differences in pathophysiology as well as epidemiology of
AKI compared to the recent years are possible. Due to limited
number of small studies, we could not conduct the pre-
specified sensitivity analyses that may have addressed the
heterogeneity introduced by different surgical procedures.
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Overall suboptimal quality and inadequate power of the
included studies limits power of our meta-analysis and
necessitates confirmation of these findings by future better-
conducted and adequately powered studies. We also did not
have information from the included studies on pretransplant
variables that may impact renal outcomes. Despite rigorous
search strategy, our funnel plot analyses suggested possi-
bility of small study publication bias. Another limitation
of our review is that information on pre-specified outcome
measures was not available in all studies despite contacting
the original authors. Despite these limitations, our review
identifies natriuretic peptides as an intervention, that is
well tolerated and possibly effective in preventing dialysis
requiring AKI, that is commonly associated with solid organ
transplantation. Our review prompts further randomized
controlled trials of this intervention.
In conclusion, thecurrent literature analyzing studies eva-
luating administration of natriuretic peptides in solid organ
transplantation setting may be associated with significant
improvements in renal outcomes. Given the limitations of
meta-analysis, these observations need to be confirmed in a
larger, adequately powered, prospective multicenter study.
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